GGrantIndex
← Leaderboards

W. Andy Tao

Purdue University

Google Scholar ↗PubMed ↗ORCID ↗
$7,729,242
Attributed
$7,729,242
Total exposure
11
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $2.1M · FY2009–24
$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$7,729,242 · 11

By mechanism

R01$2,842,430 · 3
R41$1,712,837 · 5
RF1$1,650,270 · 1
S10$968,680 · 1
R21$555,025 · 1

Top collaborators

No co-investigators on record.

Most similar at Purdue University

Same institution · by research overlap

Others in their field

Top investigators on “Proteomics”

Research focus

ProteomicsBaseProteinsResearch PersonnelMolecularMass Spectrum AnalysisDesignInnovationPhysiologicalUnited States National Institutes Of HealthCellsDetectionPolymersBiological ModelsTechnologyEventPhosphorylationPhosphoproteinsPropertyProtocols DocumentationMalignant NeoplasmsMonitorPathway InteractionsAlzheimer&Apos

Grant awards (23)

Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's Disease$386,237
R01 · FY2024 · AG · contact PI
Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's Disease$123,374
RF1 · FY2021 · AG · contact PI
Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's Disease$1,526,896
RF1 · FY2020 · AG · contact PI
Developing high throughput measurement of thiopurine in DNA by mass spectrometry$299,975
R41 · FY2020 · GM · contact PI
Developing EV surface proteins as biosignatures for Alzheimer's disease (AD)$244,909
R41 · FY2020 · AG · contact PI
Developing novel RPPA for the detection of metastatic prostate cancer$2,000
R41 · FY2018 · CA · contact PI
A Proteomic Platform to identify and Validate Biomarkers in Metabolic Syndrome and Coronary Artery Disease$301,502
R01 · FY2017 · GM · contact PI
A Proteomic Platform to identify and Validate Biomarkers in Metabolic Syndrome and Coronary Artery Disease$301,561
R01 · FY2016 · GM · contact PI
Developing novel RPPA for the detection of metastatic prostate cancer$225,000
R41 · FY2016 · CA · contact PI
Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas$328,449
R41 · FY2015 · GM · contact PI
A Proteomic Platform to identify and Validate Biomarkers in Metabolic Syndrome and Coronary Artery Disease$297,113
R01 · FY2015 · GM · contact PI
Metal ion-functionalized soluble nanopolymers: A new analytical platform for plas$312,537
R41 · FY2014 · GM · contact PI
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways$296,039
R01 · FY2014 · GM · contact PI
Proteomic differentiation of leukemia cells based on multiplexed arrays and mass$299,967
R41 · FY2013 · GM · contact PI
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways$286,263
R01 · FY2013 · GM · contact PI
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways$344,906
R01 · FY2012 · GM · contact PI
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways$29,810
R01 · FY2012 · GM · contact PI
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways$297,744
R01 · FY2011 · GM · contact PI
Proteomic Studies of Dendrimer-based Nanomedicines$183,103
R21 · FY2011 · RR · contact PI
New Proteomic Technologies for the Analysis of Tyrosine Kinase Signaling Pathways$301,255
R01 · FY2010 · GM · contact PI
Proteomic Studies of Dendrimer-based Nanomedicines$184,953
R21 · FY2010 · RR · contact PI
Acquisition of a High Resolution Orbitrap Mass Spectrometer for Analysis of Prote$968,680
S10 · FY2009 · RR · contact PI
Proteomic Studies of Dendrimer-based Nanomedicines$186,969
R21 · FY2009 · RR · contact PI